WO2003105891A3 - USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS - Google Patents

USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS Download PDF

Info

Publication number
WO2003105891A3
WO2003105891A3 PCT/EP2003/006205 EP0306205W WO03105891A3 WO 2003105891 A3 WO2003105891 A3 WO 2003105891A3 EP 0306205 W EP0306205 W EP 0306205W WO 03105891 A3 WO03105891 A3 WO 03105891A3
Authority
WO
WIPO (PCT)
Prior art keywords
hec1
antagonists
complex
cancers
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006205
Other languages
French (fr)
Other versions
WO2003105891A2 (en
Inventor
Erich A Nigg
Silvia Martin-Lluesma
Volker Stucke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Original Assignee
Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV filed Critical Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
Priority to EP03759949A priority Critical patent/EP1519736A2/en
Priority to AU2003250831A priority patent/AU2003250831A1/en
Publication of WO2003105891A2 publication Critical patent/WO2003105891A2/en
Publication of WO2003105891A3 publication Critical patent/WO2003105891A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un ou plusieurs composés anti-HEC1, un ou plusieurs antagonistes du complexe de HEC1 et/ou un ou plusieurs inhibiteurs d'anti-HEC1 pour la préparation d'une composition pharmaceutique servant à prévenir, améliorer et/ou prévenir un trouble/une maladie hyperproliférante. L'invention concerne de plus une composition pharmaceutique comprenant au moins un composé anti-HEC1, au moins un antagoniste du complexe de HEC1 et/ou au moins un inhibiteur du complexe de HEC1. L'invention concerne également un procédé d'identification d'un composé anti-HEC1, un antagoniste du complexe de HEC1 ou un inhibiteur du complexe de HEC1.The invention relates to the use of one or more anti-HEC1 compounds, one or more antagonists of the HEC1 complex and / or one or more anti-HEC1 inhibitors for the preparation of a pharmaceutical composition for preventing, improving and / or prevent a hyperproliferative disorder / disease. The invention further relates to a pharmaceutical composition comprising at least one anti-HEC1 compound, at least one antagonist of the HEC1 complex and / or at least one inhibitor of the HEC1 complex. The invention also relates to a method of identifying an anti-HEC1 compound, an antagonist of the HEC1 complex or an inhibitor of the HEC1 complex.

PCT/EP2003/006205 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer Ceased WO2003105891A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03759949A EP1519736A2 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer
AU2003250831A AU2003250831A1 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013006 2002-06-12
EP02013006.8 2002-06-12

Publications (2)

Publication Number Publication Date
WO2003105891A2 WO2003105891A2 (en) 2003-12-24
WO2003105891A3 true WO2003105891A3 (en) 2004-05-06

Family

ID=29724387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006205 Ceased WO2003105891A2 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer

Country Status (3)

Country Link
EP (1) EP1519736A2 (en)
AU (1) AU2003250831A1 (en)
WO (1) WO2003105891A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495324B1 (en) 2004-04-09 2015-03-04 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
AU2006330084A1 (en) * 2005-09-30 2007-07-05 The Regents Of The University Of California SATB1: a determinant of morphogenesis and tumor metastatis
ES2537323T3 (en) 2007-08-20 2015-06-05 Oncotherapy Science, Inc. CDCA1 peptide and pharmaceutical agent comprising it
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
CN103038231B (en) 2010-03-17 2016-04-20 泰纬生命科技股份有限公司 Modulators of HEC1 activity and methods thereof
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
SG10201506881PA (en) * 2011-11-21 2015-10-29 Taivex Therapeutics Corp Biomarkers for cancers responsive to modulators of hec1 activity
TWI640519B (en) 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Modulators of hec1 activity and methods therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEN Y ET AL: "HEC, A NOVEL NUCLEAR PROTEIN RICH IN LEUCINE HEPTAD REPEATS SPECIFICALLY INVOLVED IN MITOSIS", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 17, no. 10, 1 October 1997 (1997-10-01), pages 6049 - 6056, XP002068137, ISSN: 0270-7306 *
MARTIN-LLUESMA SILVIA ET AL: "Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2", SCIENCE (WASHINGTON D C), vol. 297, no. 5590, 27 September 2002 (2002-09-27), pages 2267 - 2270, XP002263374, ISSN: 0036-8075 *
MOSS ERIC G: "RNA interference: It's a small RNA world", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 11, no. 19, 2001, pages R772 - R775, XP002183121, ISSN: 0960-9822 *
UEDA R: "RNAI: A NEW TECHNOLOGY IN THE POST-GENOMIC SEQUENCING ERA", JOURNAL OF NEUROGENETICS, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 3/4, 2001, pages 193 - 204, XP001147227, ISSN: 0167-7063 *
WIGGE PHILIP A ET AL: "Analysis of the Saccharomyces spindle pole by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry", JOURNAL OF CELL BIOLOGY, vol. 141, no. 4, 18 May 1998 (1998-05-18), pages 967 - 977, XP002263373, ISSN: 0021-9525 *
WIGGE PHILIP A ET AL: "The Ndc80p complex from Saccharomyces cerevisiae contains conserved centromere components and has a function in chromosome segregation", JOURNAL OF CELL BIOLOGY, vol. 152, no. 2, 22 January 2001 (2001-01-22), pages 349 - 360, XP002263372, ISSN: 0021-9525 *

Also Published As

Publication number Publication date
AU2003250831A8 (en) 2003-12-31
AU2003250831A1 (en) 2003-12-31
WO2003105891A2 (en) 2003-12-24
EP1519736A2 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
MA28086A1 (en) Pyridines, Pyrazines and pyrimidines condensed with a heteroaryl ring, serving as CRF1 receptor ligands
TNSN07258A1 (en) HETEROAROMATIC QUINOLINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
DE69821132T2 (en) 1,3-THIAZOLE AS ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING ASTHMA, ALLERGIES AND DIABETES
WO2003106452A3 (en) MELANO-CONCENTRATION HORMONE RECEPTOR ANTAGONISTS
ATE252560T1 (en) STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
MA29378B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-CARBOXYARYL-SUBSTITUTED DIPHENYLUREE FOR THE TREATMENT OF CANCER
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
MA28746B1 (en) Quinazolin-4-yl-piperidine and cinnolin-4-yl-piperidine derivatives as PDE10 inhibitors for the treatment of CNS disorders
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
TNSN96104A1 (en) (1S, 2S) -1- (4-HYDROXYPHENYL) -2- (4-HYDROXY-4-PHENYLPIPERIDINE-1-YL) -1-PROPANOL TRIHYDRATE METAHENSULFONATE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
BRPI0412262A (en) azepine derivatives as pharmaceutical agents
MA27142A1 (en) PIPERAZINE DERIVATIVES HAVING ANTAGONIST ACTIVITY OF CCR1 RECEPTORS
BR0215430A (en) Compound and its uses, composition, method of treatment, method of increasing cholinergic receptor activity, method of treatment and prevention or reduction of symptoms associated with dysfunction in mammals
TNSN07071A1 (en) PYRAZOLE-SUBSTITUTED AMINOHETERO-ARYLIC COMPOUNDS AS INHIBITORS OF PROTEIN-KINASES
MA27926A1 (en) QUINOLINE AND QUINAZOLINE DERIVATIVES WITH AFFINITY TO 5HT1 RECEPTORS
MA31796B1 (en) Organic compounds
TNSN01173A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING AN NMDA RECEPTOR ANTAGONIST.
MA28269A1 (en) Substituted arylpyrazoles as parasiticidal agents
MA27133A1 (en) NEW CRYSTALLINE POLYMORPHIC FORMS OF LERCANIDIPINE HYDROCHLORIDE AND ASSOCIATED MANUFACTURING PROCESS
MA26732A1 (en) NOVEL PHARMACEUTICAL COMPOSITION COMPRISING AN OUR INHIBITOR, AND METHOD FOR THE PREPARATION THEREOF
BR9503572A (en) Compound pharmaceutical composition and method of treatment or prevention of a disease
EA200400302A1 (en) METHOD OF TREATING PRIMARY CEREBRESS
EA200601592A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PDE4 INHIBITOR OR PDE3 / 4 AND ANTAGONIST OF HISTAMINE RECEPTOR
CA2461625A1 (en) Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension
UA83870C2 (en) Bicycl 3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003759949

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003759949

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP